LRMR vs. ABUS, FULC, ALT, KMDA, PRTK, INDV, RYTM, JANX, GERN, and BHC
Should you be buying Larimar Therapeutics stock or one of its competitors? The main competitors of Larimar Therapeutics include Arbutus Biopharma (ABUS), Fulcrum Therapeutics (FULC), Altimmune (ALT), Kamada (KMDA), Paratek Pharmaceuticals (PRTK), Indivior (INDV), Rhythm Pharmaceuticals (RYTM), Janux Therapeutics (JANX), Geron (GERN), and Bausch Health Companies (BHC). These companies are all part of the "medical" sector.
Arbutus Biopharma (NASDAQ:ABUS) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations, community ranking and institutional ownership.
Larimar Therapeutics has a net margin of 0.00% compared to Larimar Therapeutics' net margin of -572.81%. Arbutus Biopharma's return on equity of -35.69% beat Larimar Therapeutics' return on equity.
Arbutus Biopharma received 396 more outperform votes than Larimar Therapeutics when rated by MarketBeat users. Likewise, 70.93% of users gave Arbutus Biopharma an outperform vote while only 63.27% of users gave Larimar Therapeutics an outperform vote.
43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are held by institutional investors. 4.0% of Arbutus Biopharma shares are held by insiders. Comparatively, 4.3% of Larimar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Larimar Therapeutics has lower revenue, but higher earnings than Arbutus Biopharma. Larimar Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, Arbutus Biopharma had 12 more articles in the media than Larimar Therapeutics. MarketBeat recorded 13 mentions for Arbutus Biopharma and 1 mentions for Larimar Therapeutics. Arbutus Biopharma's average media sentiment score of 0.59 beat Larimar Therapeutics' score of 0.28 indicating that Larimar Therapeutics is being referred to more favorably in the news media.
Arbutus Biopharma currently has a consensus price target of $4.33, suggesting a potential upside of 35.42%. Larimar Therapeutics has a consensus price target of $21.33, suggesting a potential upside of 122.45%. Given Arbutus Biopharma's higher probable upside, analysts clearly believe Larimar Therapeutics is more favorable than Arbutus Biopharma.
Arbutus Biopharma has a beta of 1.98, indicating that its share price is 98% more volatile than the S&P 500. Comparatively, Larimar Therapeutics has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500.
Summary
Larimar Therapeutics beats Arbutus Biopharma on 9 of the 16 factors compared between the two stocks.
Get Larimar Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LRMR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LRMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Larimar Therapeutics Competitors List
Related Companies and Tools
